Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome.
This study tested the hypothesis that patterns of xenobiotic metabolism in patients with eosinophilia-myalgia syndrome (EMS) differed from healthy control subjects. We determined the genotypes of 27 EMS patients with EMS and 114 control subjects for the cytochrome P450 CYP2D6 polymorphism. The metabolic phenotypes of patients with EMS for S-mephenytoin hydroxylation (n = 17) and dapsone acetylation (n = 19) were determined and compared with 29 healthy control subjects. The incidence of the CYP2D6 poor metabolizer genotype (mutant/mutant) was 0.185 in patients with EMS and 0.061 in control subjects (Mantel-Haenszel, chi 2 = 7.213, p = 0.007). The mephenytoin S/R ratios were 0.39 +/- 0.23 in patients with EMS versus 0.18 +/- 0.13 in control subjects (p < or = 0.005). There was no difference in dapsone acetylation between the two groups. A pattern of xenobiotic metabolism may play a role in the pathogenesis of EMS, but the precise role that it plays remains unclear.
Department of Medicine, Georgetown University Medical Center.
D A
DA
Flockhart
D J
DJ
Clauw
E B
EB
Sale
J
J
Hewett
R L
RL
Woosley
D000483:Alleles; D001191:Arylamine N-Acetyltransferase / Q000378:metabolism; D016022:Case-Control Studies; D003622:Dapsone / Q000378:metabolism; D003647:Debrisoquin / Q000378:metabolism; D016603:Eosinophilia-Myalgia Syndrome / Q000235:genetics* / Q000378:metabolism*; D005260:Female; D005838:Genotype; D006801:Humans; D008617:Mephenytoin / Q000378:metabolism; D010641:Phenotype; D015262:Xenobiotics / Q000378:metabolism*
D015262:Xenobiotics; D003622:Dapsone; D001191:Arylamine N-Acetyltransferase; D008617:Mephenytoin; D003647:Debrisoquin